IRWD Positive Sentiment
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
Key Takeaway: Ironwood Pharmaceuticals presented new Phase III data on apraglutide for treating adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) at ACG 2024. The results showed a consistent treatment effect across different baseline demographics and disease characteristics. This data highlights the potential of apraglutide as a viable treatment option for patients suffering from SBS-IF.
Price reaction · baseline $3.96 (2024-10-25 close) · clean, no other IRWD news in the window
day 0 close · peak
+4.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Once-weekly apraglutide demonstrated consistent treatment effects.
- Results were favorable across various baseline demographics.
- The study provides new insights into treatment for SBS-IF.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is apraglutide used for?
Apraglutide is used for treating adults with Short Bowel Syndrome with Intestinal Failure.
What were the results of the STARS Phase III study?
The STARS Phase III study showed consistent treatment effects of apraglutide across various demographics.
Where was the new data on apraglutide presented?
The new data on apraglutide was presented at ACG 2024.
Who conducted the STARS Phase III study?
The STARS Phase III study was conducted by Ironwood Pharmaceuticals.